Charles River Laboratories International (NYSE:CRL) Price Target Cut to $160.00 by Analysts at JPMorgan Chase & Co.

Key Points

• JPMorgan cut its price target on Charles River to $160 from $165 and maintained a "neutral" rating, implying about a 10.1% downside from the current share price.
• Analyst views are mixed but skew positive: out of 15 analysts 10 rate the stock a Buy, 4 Hold and 1 Sell, giving a consensus rating of "Moderate Buy" and a consensus price target of $203.85.
• In the most recent quarter CRL reported $2.39 EPS (beating estimates by $0.06) and revenue of $994.2M (also ahead of estimates), and set FY2026 guidance of $10.70–$11.20 EPS versus an analyst average forecast of $9.36.

Charles River Laboratories International (NYSE:CRL - Get Free Report) had its target price decreased by analysts at JPMorgan Chase & Co. from $165.00 to $160.00 in a note issued to investors on Monday,Benzinga reports. The firm presently has a "neutral" rating on the medical research company's stock. JPMorgan Chase & Co.'s price target indicates a potential downside of 10.14% from the company's current price.

Several other equities research analysts have also commented on the stock. Citigroup boosted their price objective on shares of Charles River Laboratories International from $200.00 to $265.00 and gave the stock a "buy" rating in a research report on Friday, January 16th. Barclays decreased their price objective on shares of Charles River Laboratories International from $215.00 to $200.00 and set an "overweight" rating on the stock in a research report on Thursday, February 19th. Weiss Ratings reissued a "sell (d)" rating on shares of Charles River Laboratories International in a research note on Wednesday, January 21st. UBS Group boosted their target price on shares of Charles River Laboratories International from $170.00 to $175.00 and gave the company a "neutral" rating in a research note on Wednesday, February 25th. Finally, Wall Street Zen downgraded shares of Charles River Laboratories International from a "buy" rating to a "hold" rating in a research note on Saturday, February 21st. Ten analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Charles River Laboratories International currently has a consensus rating of "Moderate Buy" and a consensus price target of $203.85.

Charles River Laboratories International Price Performance

Shares of Charles River Laboratories International stock traded up $2.41 on Monday, hitting $178.06. The company's stock had a trading volume of 342,184 shares, compared to its average volume of 963,151. Charles River Laboratories International has a 52-week low of $99.80 and a 52-week high of $228.88. The company has a quick ratio of 1.02, a current ratio of 1.29 and a debt-to-equity ratio of 0.67. The firm has a fifty day moving average price of $170.21 and a 200-day moving average price of $182.18. The company has a market capitalization of $8.79 billion, a P/E ratio of -60.24, a price-to-earnings-growth ratio of 2.12 and a beta of 1.61.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings data on Wednesday, February 18th. The medical research company reported $2.39 EPS for the quarter, topping the consensus estimate of $2.33 by $0.06. Charles River Laboratories International had a negative net margin of 3.59% and a positive return on equity of 15.60%. The business had revenue of $994.23 million for the quarter, compared to analyst estimates of $986.98 million. During the same period in the previous year, the firm earned $2.66 EPS. The business's revenue for the quarter was down .8% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. On average, equities research analysts expect that Charles River Laboratories International will post 9.36 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in CRL. Tema Etfs LLC acquired a new position in shares of Charles River Laboratories International during the 4th quarter valued at about $26,000. Rothschild Investment LLC boosted its position in shares of Charles River Laboratories International by 82.4% in the third quarter. Rothschild Investment LLC now owns 186 shares of the medical research company's stock worth $29,000 after acquiring an additional 84 shares during the last quarter. Atlantic Union Bankshares Corp acquired a new stake in shares of Charles River Laboratories International in the third quarter worth approximately $31,000. Los Angeles Capital Management LLC acquired a new stake in shares of Charles River Laboratories International in the fourth quarter worth approximately $42,000. Finally, Sfam LLC acquired a new stake in shares of Charles River Laboratories International in the fourth quarter worth approximately $43,000. Institutional investors and hedge funds own 98.91% of the company's stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company's core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.